Oncology Institute, Inc. (TOI)

In the past six months, TOI's stock has been impacted by several financial and operational announcements. In November 2025, TOI reported strong Q3 2025 financial results and updated its full-year 2025 revenue guidance. In March 2026, TOI reported Q4 and full-year 2025 earnings and provided 2026 guidance. The share price as of April 2, 2026, was $3.12, representing a significant increase from April 4, 2025. Analysts have issued price targets for TOI, with a median target of $6.0 in the last 6 months.

The demand for oncology services exhibits some seasonality, particularly influenced by patient deductible resets and annual drug price increases. The first quarter of the calendar year is typically the lowest for TOI due to these factors. The healthcare sector often experiences increased patient demand during the winter season. The demand for oncology services is generally expected to rise rapidly due to the aging and growth of the population and improvements in cancer survival rates.

The Oncology Institute, Inc. (TOI) operates in the Healthcare sector, focusing on Health Care Facilities and Medical Care Facilities. TOI provides comprehensive oncology care and treatment services through clinics across the United States, with a mission to heal and empower cancer patients. The company's major products and services are categorized into Specialty Pharmacy, Patient Services, and Clinical Trials and Other. The Specialty Pharmacy segment generates revenue by operating specialty and retail pharmacies. Patient Services encompass a full suite of medical oncology offerings. Through its clinical research arm, TOI provides and manages clinical trial services and research for cancer patients.

The Oncology Institute, Inc. has a significant geographic presence across the United States, with over 100 clinics and affiliate locations. As of early 2026, the company operates in five states: California, Florida, Arizona, Nevada, and Texas. The company's headquarters are located in Cerritos, California.

The Oncology Institute positions itself as a leader in cancer care, emphasizing compassionate, comprehensive, and quality oncology care in a community setting. Their mission focuses on healing and empowering cancer patients through compassion, innovation, and state-of-the-art medical care. The company's consistent messaging around value-based care, community-centric approach, and positive financial growth in 2025 and projected for 2026 would generally contribute positively to its brand perception. The company's partnership with Ascertain to co-develop AI-based automation for administrative workflows could also be seen as a positive step towards innovation and efficiency.

The ownership structure of TOI stock is a mix of institutional, retail, and individual investors. Institutional owners hold a total of 38,648,034 shares. Individual investors collectively hold a significant portion of the company's shares. Insiders own approximately 13.03% of the company's stock.